Recurrence patterns in a large contemporary cohort of patients with non-muscle invasive bladder cancer

Jasper P. Hof,[1] Lambertus A. Kiemeney,[1,2] Katja K.H. Aben,[1,3] Antoine G. van der Heijden,[2] Alina Vrieling,[1*] Sita H. Vermeulen[1*]

[1]Radboud university medical center, IQ Health science department, Nijmegen, The Netherlands

[2]Radboud university medical center, Department of Urology, Nijmegen, The Netherlands

[3]Netherlands Comprehensive Cancer Organization, Department of Research and Development, Utrecht, The Netherlands

[*]These authors share senior authorship

Abstract

Background and Objective: Patients with non-muscle invasive bladder cancer (NMIBC) frequently experience recurrences, yet, the timing and characteristics of subsequent recurrences are understudied. We aim to describe subsequent recurrences in a large, contemporary, population-based cohort.

Methods: We included 1,915 patients from the UroLife study and the Nijmegen Bladder Cancer Study, diagnosed with primary NMIBC between 2011 and 2021. The conditional 1-, 3- and 5-year risks of first to fourth recurrence were calculated using Kaplan-Meier risks, stratified by clinicopathological factors. Patterns of subsequent tumours were described and visualised.

Key Findings and Limitations: We observed 671 first recurrences and 400 subsequent recurrences. The 3-year conditional recurrence risks for first, second and third recurrence were 31%, 45% and 54%, respectively, and were similar for NMIBC risk groups. Recurrence after a low-, intermediate- or high-risk tumour (either primary or recurrent) was again of low-, intermediate- or high-risk in 74%, 62% and 44% of cases, respectively. Ten patients with low/intermediate-risk NMIBC and 89 patients with high-risk NMIBC progressed to muscle-invasive or metastatic bladder cancer. Seven out of these ten (70%) and 13 out of these 89 (15%) patients had a high-risk recurrence before progression. This study was limited to a patient cohort from The Netherlands.

Conclusions and Clinical Implications: Our study provides novel and reliable estimates of recurrence rates and patterns in NMIBC from a large, contemporary, population-based cohort. Recurring NMIBC tumours often exhibit similar clinicopathological characteristics, and patients with primary low- or intermediate-risk NMIBC who progress to MIBC/mBC often have a high-risk recurrence before progression. These results can inform research into NMIBC recurrences and surveillance schedules.

Introduction

Approximately 75% of patients with bladder cancer are diagnosed with non-muscle invasive bladder cancer (NMIBC), which is generally associated with a favourable survival (1-3). Yet, patients with NMIBC face a high risk of recurrence and a substantial risk of progression to muscle-invasive bladder cancer (MIBC) or metastatic disease (mBC) (1), necessitating an intensive follow-up schedule with frequent invasive cystoscopies (2, 3).

Extensive research has been conducted into the clinical and pathological characteristics that predict NMIBC recurrence and progression (4-11). Resulting risk classification models that classify NMIBC tumours into low-, intermediate-, high-, or very high-risk are used in clinical practice (3, 12). However, most studies primarily focused on the first recurrence as clinical outcome, while the risk and timing of subsequent recurrences remain relatively understudied. Yet, subsequent recurrences have been reported to comprise 47% up to 62% of all observed recurrences (11, 13-16).

Although prior recurrence is a predictor in NMIBC risk classifications (5, 14), data on risks of subsequent NMIBC recurrences are limited (11, 14, 15, 17, 18), and no study has explored the patterns of tumour characteristics of these recurrences, including risk group classification. Also, previous studies suffer from limitations such as the use of data that can now be considered outdated (14, 16), relatively small sample sizes (15, 17), or restriction to an intermediate-risk group (17).

In this study, we addressed this gap by investigating the timing and characteristics of recurrences in a contemporary group of patients diagnosed with low- to very high-risk NMIBC. We used two large population-based Dutch bladder cancer cohorts: the UroLife study and the Nijmegen Bladder Cancer Study (NBCS), in which recurrences were systematically registered, providing a robust foundation for our investigation.

Materials and Methods

Study population

Patients diagnosed with NMIBC were selected from UroLife and the NBCS. Both studies identified eligible patients through the Netherlands Cancer Registry (NCR), which records data from all cancers diagnosed in The Netherlands since 1989. The UroLife study (19) (N = 1,515) is a prospective multicenter cohort study conducted in 22 hospitals in the east, south and central parts of The Netherlands. Eligible patients were between 18 and 80 years old, underwent a transurethral resection of the bladder tumour (TURBT), and were newly diagnosed with histologically confirmed primary NMIBC of stages Ta (May 2014-April 2017), T1 (May 2014-April 2021), or Tis (May 2014-April 2017). Patients were invited for participation approximately 4 weeks after diagnosis. Response rate was 52% and participants were comparable to patients declining participation with respect to age, sex, tumour stage and tumour grade. Ethical approval was provided by the Committee for Human Research region Arnhem-Nijmegen (CMO 2013-494).

In the NBCS (20) patients diagnosed with bladder cancer in one of seven hospitals in the eastern part of The Netherlands during the period 1995-2015 were enrolled. Patients were considered eligible if diagnosed at or before the age of 75, alive at time of invitation for the study and able to read/understand the Dutch language. Invitation was performed in six separate phases or batches. For the current study, we only used the three most recent NBCS batches with patients who were diagnosed between 2011-2015 and invited for participation in 2017 and 2019 (N = 472). The NBCS was approved by the Committee for Human Research region Arnhem-Nijmegen (CMO 2005-315).

For both UroLife and NBCS, relevant data for this study on patient (age, sex) and tumour characteristics (tumour stage, tumour grade, CIS, focality), and outcomes were obtained by a medical file review by NCR data managers. Patients with upper tract urothelial carcinoma before (N = 10) or within 3 months of primary diagnosis (N = 26) were excluded, as were duplicate records of patients who participated both in UroLife and NBCS (n=36).

Definition of recurrence and progression

Recurrence is defined as either a (i) histologically confirmed bladder tumour based on a trans-urethral resection of bladder tumour (TURBT), (ii) report of fulguration, (iii) histologically confirmed bladder tumour found after cystectomy, or (iv) progression to MIBC or mBC after an initial NMIBC diagnosis. Fulguration only counted as recurrence if it occurred at least six months after previous recurrence, and was coded as TaG1 recurrence.

Notably, a recurrence can only occur after the patient achieved a ‘tumour-free status’. The definition for tumour-free status depends on the stage of the previous bladder tumour:

- For stage Ta or T1 tumours, an individual was considered tumour-free after undergoing radical TURBT or re-TURBT, or, in case of nonradical (re-)TURBT, after tumour-negative cystoscopy;
- For stage Tis or concomitant carcinoma in situ (CIS), an individual was considered tumour-free after tumour-negative cystoscopy, and, if available, negative cytology and negative biopsy.

The requirement for negative cystoscopy and, if available, negative cytology and biopsies ensured that for (concomitant) CIS, only those patients who had a complete response after treatment were at risk of recurrences. As a result, 42 patients with primary (concomitant) CIS who were never at risk of recurrence were excluded from analysis of recurrence. However, they remained at risk of progression and were hence included in the progression analysis.

Progression to MIBC or mBC was defined as (i) the occurrence of a bladder tumour of stage T2 or higher, confirmed by pathology or imaging, (ii) positive lymph node status, or (iii) distant metastasis.

Patients were no longer at risk of recurrence after either (i) the last contact between patient and urologist; (ii) radical cystectomy; (iii) progression to MIBC or mBC; or (iv) diagnosis of another type of cancer with metastasis, whichever came first. Patients were no longer at risk of progression to MIBC/mBC after either (i) the last contact between patient and urologist; or (ii) diagnosis of another type of cancer with metastasis, whichever came first. Recurrence-free survival was defined as the time between the date of achieving the tumour-free status and date of subsequent recurrence or end of at-risk period, whichever came first.

Definition of risk groups

Bladder tumours were categorized based on the EAU risk group classification (2021) by Sylvester *et al.*, which is based on stage, grade, (concomitant) CIS, prior recurrence, focality, age, and tumour size (5). We however adopted a slightly modified version in which prior NMIBC recurrence was not included as risk factor, to ensure comparable classification of primary and recurrent bladder tumours (see **Supplemental Table 1**). Also, tumour diameter was omitted, since this was not systematically registered in the medical records by Dutch urologists and therefore mostly missing. Consequently, a small percentage of tumours was assigned to a lower risk group compared to the EAU risk group classification.

Data analysis

We assessed the 1-year, 3-year, and 5-year risk of first to fourth recurrence, conditional on prior recurrence, based on Kaplan-Meier (KM) risk. To investigate whether recurrence patterns differ by recency of diagnosis, we also performed these analyses separately for patients with a primary NMIBC diagnosis before and after 2016 (median year of diagnosis). We also stratified KM analyses by treatment, as NMIBC prognosis is affected by treatment. In addition, we stratified the KM risks of first to fourth recurrence by sex to explore

possible sex-specific recurrence patterns, as women have been reported to have poorer NMIBC prognosis (21).

Next, we described the transitions between risk groups, grade, stage, and tumour location across subsequent recurrences within patients. These were also visualised using alluvial diagrams. All KM risks and transitions between risk groups across subsequent recurrences were evaluated for the total cohort and stratified by risk group of the primary tumour. Finally, we described the recurrence patterns of the patients who progressed to MIBC or mBC using swimmer plots.

All analyses were performed in R (version 4.1.3). KM plots, alluvial diagrams and swimmer plots were visualised using the ggplot2 package (version 3.3.6).

Results

Cohort characteristics

Patient and tumour characteristics at time of primary diagnosis and at time of first to fourth recurrence are described in detail in **Table 1**. A total of 1,915 patients with a primary diagnosis of NMIBC were included, and 1,071 recurrences were observed. The median follow-up time for the complete cohort was 59 months (interquartile range (IQR): 38-67 months) and varied per risk group due to the extended inclusion of T1 patients in the UroLife study (62, 62, 46, and 31 months for low, intermediate, high, and very high-risk NMIBC, respectively). Cystoscopy surveillance schemes and treatment of primary NMIBC tumours are based on the Dutch Urology Association guidelines that follow EAU guidelines, but, as expected, deviate in clinical practice (**Table 2** and **Supplementary Table 2**).

Incidence and timing of recurrences

KM curves for first to fourth recurrence are displayed in **Figure 1** (KM risks and 95% confidence intervals in **Supplementary Table 3)**. The 1-year, 3-year, and 5-year KM risks of a first recurrence in the total population were 15%, 31%, and 39%, respectively, and were comparable for the different risk groups. However, we found that the KM risks of subsequent recurrences (i.e., after the first) were slightly higher in the primary intermediate- or high-risk group compared to the primary low risk group. We observed an increased risk for subsequent recurrences: the 1-year, 3-year, and 5-year conditional KM recurrence risks of a second recurrence after the first recurrence were 24%, 47%, and 52%, whereas the 1-year, 3-year, and 5-year conditional KM recurrence risks of a third recurrence were even higher: 28%, 55%, and 60%, respectively.

We found similar recurrence risks of first to fourth recurrence after stratifying by sex and year of diagnosis of primary tumour (**Supplementary Figure 1**) but observed lower rates of a first recurrence for primary high-risk patients who received a re-TURBT compared to patients without re-TURBT, and high-risk patients who received BCG induction compared to patients not receiving BCG induction therapy (**Supplementary Figure 2**).

Patterns of recurrences

A recurrence after a low, intermediate or high/very high-risk tumour (either primary or recurrence) was again of low, intermediate or high-risk in 74%, 62% and 44% of cases (**Figure 2**). Concordance was even higher when focusing on grade and stage: a recurrence after low-grade NMIBC (grade 1, 2, or 2A) was also of low grade in 91% of cases, while a recurrence after high-grade NMIBC was also of high grade in 80% of cases. As for stage, 87% of recurrences after a Ta tumour were again of stage Ta. By contrast, only 25% of recurrences after a T1 tumour were again stage T1, while respectively 38%, 15% and 19% of recurrences

were Ta, (concomitant) CIS, or MIBC/mBC. Finally, 52% of recurrences after (concomitant) CIS were again (concomitant) CIS (**Supplementary Figures 3 and 4**).

Data on tumour location was available for 1,492 of the 1,915 primary tumours and 667 of the 1,071 recurrences. In 78% of recurrences with tumour location available, the initial and recurrent tumour were of the same coded site. For the subgroup of patients who received a re-TURBT of an initial high or very high-risk tumour, 95 out of 140 recurrences (68%) with known tumour location were of the same location as the previous tumour, and in the subgroup of patients without re-TURBT, 52 out of 72 recurrences (72%) were of the same location (Supplementary Figure 5).

In total, 99 patients progressed to MIBC or mBC. The disease course of these patients before progression is visualised in **Figure 3**. Among the patients who progressed to MIBC or mBC, one patient was diagnosed with primary low-risk NMIBC, 9 with primary intermediate-risk NMIBC, and 89 with primary high or very high-risk NMIBC. The patient with primary low-risk NMIBC had a concomitant Ta + CIS recurrence before progressing to a T2 tumour. Among the 9 patients with primary intermediate-risk NMIBC, eight patients had a recurrence before progression. Six of them had a high-risk grade 2B or 3 recurrence before progressing to MIBC or mBC; the other two experienced an intermediate-risk recurrence before progression.

Among the 89 patients with primary high or very high-risk NMIBC, 65 (73%) experienced progression to stage T2 or higher, 29 (33%) were positive for lymph node metastasis and 35 (39%) experienced distant metastasis. Only 19 (21%) patients experienced a recurrence before progression, of which 13 (15%) were high- or very high-risk. However, it should be noted that 9 of the 89 patients were never tumour-free after primary (concomitant) CIS, and therefore never at risk of recurrence. More details of patients who progressed to MIBC, stratified by risk category of primary tumour, are included in Supplemental Table X.

Discussion

In this large contemporary NMIBC cohort, we investigated patterns of multiple recurrences. We extensively described the transitions, timings and characteristics of subsequent recurrences, as well as the course of the disease before progression to MIBC or mBC. Our findings provide novel insights into the course of multiple recurrences in NMIBC under the current guidelines, which can be used for future studies into surveillance schedules and facilitate research into NMIBC recurrence mechanisms.

One pivotal outcome of our research is the observation that recurring tumours often manifest similar clinicopathological characteristics, such as similar grade, stage, and risk group. This phenomenon was previously reported in literature (15, 22), but now quantitatively substantiated by our study. Notably, among the patients with primary low- or intermediate-risk NMIBC progressing to MIBC or mBC, we observed a pattern in which progression was preceded by a high- or very high-risk recurrence in 70% of the patients. Conversely, primary high- or very high-risk NMIBC patients often exhibited a direct progression to MIBC or mBC, with only 21% reporting any recurrence before progression. We also observed that recurrence risks increased with the number of previous recurrences, in line with current NMIBC risk calculators (5, 6)**.**

Prior studies have explored patterns of subsequent NMIBC recurrences, focusing on recurrence mechanisms (15), statistical methods (14) or risk factors for multiple recurrences (13, 16-18). Despite having a relatively long median follow-up time in the combined dataset of UroLife and NBCS, other studies generally report higher recurrence rates (see **Supplementary Table 4**). This may be due to our stricter definition of NMIBC recurrences, which requires a tumour-free status before a recurrence, but also due to differences in patient populations or intensification of NMIBC treatment over time.

Our study's primary strength lies in the size and quality of the combined datasets from UroLife and NBCS enabling in-depth exploration of recurrence patterns up to the fourth recurrence and stratification on various clinical characteristics of patients. However, we recognise some limitations of the study. Our population-based cohort was not treated in full concordance with the current EAU guidelines. For example, only 61% of low- or intermediate-risk patients received a single post-operative instillation of chemotherapy. However, this is in line with earlier reports on adherence to guidelines (12, 24, 25).Our study thus offers a realistic insight into recurrence patterns in a contemporary NMIBC population as well as insights into how these patterns differ according to treatment. We were unable to incorporate tumour size in our definition of NMIBC risk groups. As a result, a small percentage of tumours may be assigned to a lower risk group compared to assignment based on the EAU risk group classification. Finally, this study was limited to two Dutch bladder cancer studies, and replication in other populations is needed to externally validate our findings.

Conclusions

Using a large, contemporary cohort, we revealed key patterns in NMIBC recurrences. We demonstrated that recurring NMIBC tumours often manifest similar clinicopathological characteristics. Over half of patients with primary low- or intermediate-risk NMIBC who progress to MIBC or mBC experience a high or very high-risk recurrence before progression, whereas primary high-risk NMIBC patients often exhibit direct progression to MIBC/mBC. The results of this study can assist in the optimization of the design of future studies into factors that affect NMIBC outcomes. Also, our study highlights relevant areas for further research, including research into specific patient subgroups with distinct recurrence patterns.

Funding/Support and role of the sponsor

SHV is supported by a grant from the Netherlands Organization for Scientific Research (NWO Vidi 91717334). The UroLife study was financially supported by Alpe d'HuZes/Dutch Cancer Society (KUN 2013-5926) and Dutch Cancer Society (2017-2/11179).

Acknowledgement

The authors thank all the patients who participated in UroLife and thank the following hospitals for their involvement in recruitment for the UroLife study: Amphia Ziekenhuis, Breda/Oosterhout (D.K.E. van der Schoot); Ziekenhuis Bernhoven, Uden (A.Q.H.J. Niemer); Canisius-Wilhelmina Ziekenhuis, Nijmegen (D.M. Somford); Catharina Ziekenhuis, Eindhoven (E.L. Koldewijn); Deventer Ziekenhuis, Deventer (P.L.M. van den Tillaar); Elkerliek Ziekenhuis, Helmond (E.W. Stapper †, P.J. van Hest); Gelre Ziekenhuizen, Apeldoorn/Zutphen (D.M. Bochove-Overgaauw); Isala Klinieken, Zwolle (E. te Slaa); Jeroen Bosch Ziekenhuis, 's-Hertogenbosch (S. van der Meer); Meander Medisch Centrum, Amersfoort (F.S. van Rey); Medisch Spectrum Twente, Enschede (M. Asselman); Maxima Medisch Centrum, Veldhoven/Eindhoven (L.M.C.L. Fossion, K. de Laet); Maasziekenhuis Pantein, Boxmeer (E. van Boven); Radboudumc, Nijmegen; Rijnstate, Arnhem/Velp/Zevenaar (C.J. Wijburg); Slingeland Ziekenhuis, Doetinchem (A.D.H. Geboers); St. Anna Ziekenhuis, Geldrop (A. Sonneveld); Elisabeth-TweeSteden Ziekenhuis, Tilburg/Waalwijk (P.J.M. Kil, B.P. Wijsman); St. Jansdal Ziekenhuis, Harderwijk (W.J. Kniestedt); VieCuri, Venlo (G. Yurdakul, A.H.P. Meier); Ziekenhuis Gelderse Vallei, Ede (M.D.H. Kortleve); Ziekenhuisgroep Twente, Almelo/Hengelo (E.B. Cornel). The authors thank the registration team of the Netherlands Comprehensive Cancer Organisation (IKNL) for the collection of data for the Netherlands Cancer Registry as well as IKNL staff for scientific advice.

References

1. Kirkali Z, Chan T, Manoharan M, Algaba F, Busch C, Cheng L, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology. 2005;66(6 Suppl 1):4-34.
2. Witjes JA. Follow-up in non-muscle invasive bladder cancer: facts and future. World J Urol. 2021;39(11):4047-53.
3. Babjuk M, Burger M, Capoun O, Cohen D, Comperat EM, Dominguez Escrig JL, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). Eur Urol. 2022;81(1):75-94.
4. van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56(3):430-42.
5. Sylvester RJ, Rodriguez O, Hernandez V, Turturica D, Bauerova L, Bruins HM, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480-8.
6. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49(3):466-5; discussion 75-7.
7. Lammers RJM, Witjes WPJ, Hendricksen K, Caris CTM, Janzing-Pastors MHC, Witjes JA. Smoking Status Is a Risk Factor for Recurrence After Transurethral Resection of Non–Muscle-Invasive Bladder Cancer. European Urology. 2011;60(4):713-20.
8. Evers J, Grotenhuis AJ, Aben KKH, Kiemeney L, Vrieling A. No clear associations of adult BMI and diabetes mellitus with non-muscle invasive bladder cancer recurrence and progression. PLoS One. 2020;15(3):e0229384.
9. Zuniga KB, Graff RE, Feiger DB, Meng MV, Porten SP, Kenfield SA. Lifestyle and Non-muscle Invasive Bladder Cancer Recurrence, Progression, and Mortality: Available Research and Future Directions. Bladder Cancer. 2020;6(1):9-23.
10. Garg T, McMullen CK, Leo MC, O'Keeffe-Rosetti MC, Weinmann S, Nielsen ME. Predicting risk of multiple levels of recurrence and progression after initial diagnosis of nonmuscle-invasive bladder cancer in a multisite, community-based cohort. Cancer. 2021;127(4):520-7.
11. Deng N, Chen JX, Chen LW, Qiu SP, Li XF, Wang DH. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection. Chin Med J (Engl). 2012;125(20):3681-6.
12. Hendricksen K, Aziz A, Bes P, Chun FK-H, Dobruch J, Kluth LA, et al. Discrepancy between European Association of urology guidelines and daily practice in the management of non–muscle-invasive bladder cancer: results of a European survey. European urology focus. 2019;5(4):681-8.
13. Waseda Y, Kobayashi S, Kanda E, Yokoyama M, Ishioka J, Matsuoka Y, et al. Impact of Bladder Neck Involvement on Recurrence in Patients With Non-muscle-invasive Bladder Cancer: An Analysis Based on a Time-dependent Model. Clin Genitourin Cancer. 2020;18(2):e62-e70.
14. Smedinga H, Steyerberg EW, Beukers W, van Klaveren D, Zwarthoff EC, Vergouwe Y. Prediction of Multiple Recurrent Events: A Comparison of Extended Cox Models in Bladder Cancer. Am J Epidemiol. 2017;186(5):612-23.
15. Bryan RT, Collins SI, Daykin MC, Zeegers MP, Cheng KK, Wallace DM, Sole GM. Mechanisms of recurrence of Ta/T1 bladder cancer. Ann R Coll Surg Engl. 2010;92(6):519-24.
16. Simon M, Bosset PO, Rouanne M, Benhamou S, Radulescu C, Molinie V, et al. Multiple recurrences and risk of disease progression in patients with primary low-grade (TaG1) non-muscle-invasive bladder cancer and with low and intermediate EORTC-risk score. PLoS One. 2019;14(2):e0211721.
17. Sharma V, Chamie K, Schoenberg M, Lee VS, Fero K, Lec P, et al. Natural history of multiple recurrences in intermediate-risk non-muscle invasive bladder cancer: lessons from a prospective cohort. Urology. 2022.

18. Miyake M, Nishimura N, Nakai Y, Fujii T, Owari T, Hori S, et al. Photodynamic Diagnosis-Assisted Transurethral Resection Using Oral 5-Aminolevulinic Acid Decreases the Risk of Repeated Recurrence in Non-Muscle-Invasive Bladder Cancer: A Cumulative Incidence Analysis by the Person-Time Method. Diagnostics (Basel). 2021;11(2).
19. de Goeij L, Westhoff E, Witjes JA, Aben KK, Kampman E, Kiemeney LA, Vrieling A. The UroLife study: protocol for a Dutch prospective cohort on lifestyle habits in relation to non-muscle-invasive bladder cancer prognosis and health-related quality of life. BMJ Open. 2019;9(10):e030396.
20. Grotenhuis AJ, Dudek AM, Verhaegh GW, Witjes JA, Aben KK, van der Marel SL, et al. Prognostic relevance of urinary bladder cancer susceptibility loci. PLoS One. 2014;9(2):e89164.
21. Uhlig A, Strauss A, Seif Amir Hosseini A, Lotz J, Trojan L, Schmid M, Uhlig J. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. Eur Urol Focus. 2018;4(6):924-36.
22. Mariappan P, Smith G, Lamb AD, Grigor KM, Tolley DA. Pattern of recurrence changes in noninvasive bladder tumors observed during 2 decades. J Urol. 2007;177(3):867-75; discussion 75.
23. Maas M, Bedke J, Stenzl A, Todenhöfer T. Can urinary biomarkers replace cystoscopy? World journal of urology. 2019;37:1741-9.
24. Mori K, Miura N, Babjuk M, Karakiewicz PI, Mostafaei H, Laukhtina E, et al. Low compliance to guidelines in nonmuscle-invasive bladder carcinoma: A systematic review. Urol Oncol. 2020;38(10):774-82.
25. Struck JP, Hennig MJ, Hupe MC, Moharam N, Paffenholz P, Nestler T, et al. Discrepancy between German S3 guideline recommendations and daily urologic practice in the management of nonmuscle invasive bladder cancer: results of a binational survey. Urologia Internationalis. 2023;107(1):35-45.

Tables and Figures

Table 1. ***Characteristics of all observed tumours in UroLife and the Nijmegen Bladder Cancer Study****. Tumour characteristics are presented for all primary tumours (i.e., the complete cohort at time of diagnosis), and all first, second, third and later recurrences, thereafter. Due to missing values, clinical characteristics were not available for all tumours.*

	Primary[1]	**Recurrence 1**	**Recurrence 2**	**Recurrence 3**	**Recurrence ≥4**
N	1915	671	241	100	59
Age, median (IQR)	67 (61, 72)	67 (61, 73)	67 (61, 74)	68 (62, 75)	70 (64, 77)
Male sex, *n* (%)	1515 (79)	525 (78)	174 (72)	74 (74)	47 (80)
Stage, *n* (%)					
Ta	1113 (58)	472 (71)	184 (77)	80 (81)	49 (83)
T1	757 (40)	73 (11)	11 (5)	7 (7)	2 (3)
Tis	44 (2)	65 (10)	25 (10)	5 (5)	3 (5)
>2	-	41 (6)	10 (4)	3 (3)	1 (2)
Missing	1 (0)	9 (1)	8 (3)	4 (4)	4 (7)
Concomitant CIS, *n* (%)	233 (12)	32 (5)	7 (3)	3 (3)	2 (3)
N stage, *n* (%)					
0	1915 (100)	618 (97)	230 (99)	95 (99)	58 (98)
1	-	4 (1)	1 (0)	1 (1)	-
2	-	11 (2)	2 (1)	-	1 (2)
3	-	3 (0)	-	-	-
M stage, *n* (%)					
0	1915 (100)	613 (96)	228 (98)	95 (99)	58 (98)
1	-	2 (0)	-	-	-
1A	-	3 (0)	1 (0)	-	-
1B	-	20 (3)	4 (2)	1 (1)	1 (2)
Grade, *n* (%)					
1	328 (17)	130 (19)	61 (25)	22 (22)	13 (22)
2	443 (23)	136 (20)	51 (21)	19 (19)	11 (19)
2A	247 (13)	120 (18)	43 (18)	28 (28)	16 (27)
2B	152 (8)	53 (8)	21 (9)	13 (13)	11 (19)
3	688 (36)	164 (24)	37 (15)	13 (13)	4 (7)
Missing	57 (3)	66 (10)	28 (12)	5 (5)	4 (7)
Morphology, *n* (%)					
Urothelial carcinoma	1906 (100)	668 (100)	241 (100)	100 (100)	59 (100)
Small cell carcinoma	2 (0)	-	-	-	-
Mixed small cell carcinoma	3 (0)	2 (0)	-	-	-
Sarcomatoid	1 (0)	-	-	-	-
Micropappilary urothelial carcinoma	2 (0)	1 (0)	-	-	-
Mucinous adenocarcinoma	1 (0)	-	-	-	-
Lymphovascular invasion, *n* (%)	21 (1)	9 (1)	0 (0)	0 (0)	0 (0)
Risk group, *n* (%)					
Low Risk	519 (27)	199 (30)	81 (34)	37 (37)	16 (27)
Intermediate Risk	570 (30)	228 (34)	88 (37)	41 (41)	32 (54)
High Risk	641 (33)	138 (21)	43 (18)	14 (14)	7 (12)
Very High Risk	158 (8)	10 (1)	2 (1)	-	-
Missing	27 (1)	39 (6)	14 (6)	4 (4)	3 (5)
Focality, *n* (%)					
Multifocal	630 (33)	258 (38)	116 (48)	51 (51)	30 (51)
Unifocal	1257 (66)	405 (60)	116 (48)	42 (42)	27 (46)
Missing	28 (1)	8 (1)	9 (4)	7 (7)	2 (3)
Smoking[2], *n* (%)					
Never	293 (15)	-	-	-	-

Former	1179 (62)	-	-	-	-
Current	407 (21)	-	-	-	-
Missing	36 (2)	-	-	-	-

IQR: interquartile range. [1]The median follow-up time of patients experiencing no recurrences in the low-, intermediate-, high-, and very high-risk group were respectively, 62, 61, 52 and 40 months. [2]Smoking is only reported at primary diagnosis.

Table 2. ***Treatment of primary tumours, stratified by risk group****.*

	Low risk	Intermediate risk	High risk	Very high risk
N	519	570	641	158
re-TURBT*, *n* (%)	38 (7)	121 (21)	455 (71)	122 (77)
Radical cystectomy , *n* (%)	3 (1)	10 (2)	22 (3)	9 (6)
Single post-operative instillation of chemotherapy, ***n* (%)**	317 (61)	345 (61)	225 (35)	42 (27)
Mitomycine, ***n* (%)**[x]	205 (65)	258 (75)	164 (73)	32 (76)
Epirubicine, ***n* (%)**	103 (32)	59 (17)	52 (23)	7 (17)
Gemcitabine, ***n* (%)**	-	-	-	-
Unspecified, ***n* (%)**	9 (3)	28 (8)	9 (4)	3 (7)
Adjuvant chemotherapy, *n* (%)	107 (21)	185 (32)	139 (22)	18 (11)
Mitomycine, ***n* (%)**[x]	71 (66)	153 (83)	82 (60)	8 (44)
No. instillations, median (IQR)	9 (7, 9)	9 (7, 9)	8 (5, 9)	8 (4, 13)
Epirubicine, ***n* (%)**	33 (31)	17 (9)	14 (10)	1 (6)
No. instillations, median (IQR)	2 (1, 7)	6 (2, 8)	1 (1, 9)	1 (1, 1)
Gemcitabine, ***n* (%)**	-	6 (3)	39 (28)	8 (44)
No. instillations, median (IQR)	-	6 (6, 8)	6 (5, 11)	7 (6, 9)
Unspecified, ***n* (%)**	3 (3)	9 (5)	2 (1)	1 (6)
No. instillations, median (IQR)	11 (6, 12)	9 (7, 9)	-	-
Induction BCG[+], *n* (%)	3 (1)	85 (15)	472 (74)	108 (68)
No. instillations, median (IQR)	6 (6, 6)	6 (6, 6)	6 (6, 6)	6 (6, 6)
Maintenance BCG[+], *n* (%)	3 (1)	70 (12)	317 (49)	80 (51)
No. instillations, median (IQR)	10 (8, 12)	10 (9, 15)	9 (6, 15)	9 (3, 12)

*re-TURBT was performed for 446 (72%) out of 618 papillary high-risk tumours and 110 (82%) out of 134 papillary very high-risk tumours. [x]Percentage of patients receiving a type of single instillation- or adjuvant chemotherapy is reported relative to patient subgroup. [+]Induction BCG and maintenance BCG are defined in Supplementary Table 5.



Figure 1. Recurrence risk of NMIBC for the first to fourth recurrence, for complete cohort and stratified by risk group of primary tumour. *Recurrence risk is reported as Kaplan-Meier (KM) risks, based on time to recurrence since tumour-free status. For all KM curves, the 1-, 3-, and 5-year risks are included in the figure, and are reported with 95% confidence intervals in Supplementary Table 3. Note that some numbers at risk of risk groups may not add up to numbers of the full population due to missing values in risk groups.*



Figure 2. Alluvial diagram describing transitions of risk groups and progression within patients across subsequent recurrences, for complete cohort and stratified by risk group of primary tumour. *The vertical bars indicate the distribution of risk groups of tumours for the primary tumour and first to fourth recurrences. The numbers on top of each bar indicate the numbers of tumours and proportion in this (sub-)population. The stream fields between the blocks indicate the individual changes in risk group for subsequent recurrences. We note that risk group was not available for all tumours due to missing values.*



Figure 3. Swimmer plot describing the timing of recurrences, cystectomy and progression to MIBC or mBC for patients who progressed to MIBC or mBC*. Patients are categorized based on EAU group of primary tumour and ordered on the y-axis based on duration of follow-up time (depicted as grey line). All observed recurrences or cystectomy before progression to MIBC or mBC are plotted on the relevant y-value of the individual.*